Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
RX-3117 showed Preliminary Efficacy in Pancreatic Cancer Patients for Whom Three or More Prior Therapies had been Ineffective Supinoxin™ was Safe and Well Tolerated in Patients with Advanced...
-
ROCKVILLE, Md., Oct. 04, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing next generation targeted therapeutics for the...
-
ROCKVILLE, Md., Sept. 14, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) today announced it has entered into a definitive agreement with institutional investors to purchase...
-
Predefined Criteria for Preliminary Efficacy Achieved in Pancreatic Cancer Patients for Whom Three Prior Therapies had been Ineffective RX-3117 was Safe and Well Tolerated Results Have Been...
-
ROCKVILLE, Md., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the...
-
ROCKVILLE, Md., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of...
-
ROCKVILLE, Md., July 11, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of...
-
ROCKVILLE, Md., June 06, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment...
-
ROCKVILLE, Md., May 23, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment...
-
Progresses Novel Targeted Anti-Cancer Therapies in Clinical Development Initiates Phase Ib/IIa Clinical Trial of RX-3117 and Begins Enrollment in Phase IIa Randomized Clinical Trial of...